The Impact on Therapeutic Effect and Tolerance of Treatment for Patients With Hepatocellular Carcinoma in Transcatheter Arterial Chemoembolization (TACE) of Dexamethasone Application: A Random, Double-blind, Controlled, Clinical Trial.

Inclusion Criteria: * older than 18 years old; * ECOG PS\<3; * proven hepatocellular carcinoma according patological examination or EASL/AASLD diagnostic criteria; * meeting at least 1/4: 1) multiple nodules, 2) single tumor but not suitable for resection, 3) vascular invasion exists, 4) distant metastasis excluding CNS and bone * not previous treated for tumor; * Child-Pugh A or B; * at least one measurable lesion according mRECIST; * cannot afford sorafenib; * the lab test could meet: neutrophil count≥1.5×109/L; hemoglobin≥80g/L; platelet count≥60×109/L; serum albumin≥28g/L; total bilirubin\<3-times upper limit of normal; ALT\<5-times upper limit of normal; AST\<5-times upper limit of normal; serum creatine\<1.5-times upper limit of normal; PT≤upper limit of normal plus 6 seconds; INR≤2.3 * sign up consent; * unrolled by other clinical trials about hepatocellular carcinoma. Exclusion Criteria: * cannot tolerate TACE; * CNS or bone metastasis exits; * known history of other malignancy; * be allergic to related drugs; * underwent organ transplantation before; * be treated before (interferon included); * known history of HIV infection; * known history of drug or alcohol abuse; * have GI hemorrage or cardiac/brain vascular events within 30 days; * pregnancy;